Cardiac amyloidosis: Shifting our impressions to hopeful

Current Heart Failure Reports

Volumn 3, Issue 2, 2006, Pages 64-71

  Sawyer, Douglas B ^b   Skinner, Martha ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIFLUNISAL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MELPHALAN; PREDNISONE; VASODILATOR AGENT;

AMYLOIDOSIS; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; FATIGUE; HEART AMYLOIDOSIS; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; INCIDENCE; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; SYNCOPE; TREATMENT OUTCOME;

AMYLOIDOSIS; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; PROGNOSIS;

EID: 33750379416     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-006-0004-z     Document Type: Review

References (41)

1. Falk RH: Diagnosis and management of the cardiac amyloidoses. Circulation 2005, 112:2047-2060.
2. Hassan W, Al-Sergani H, Mourad W, Tabbaa R: Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J 2005, 32:178-184.
3. O'Hara CJ, Falk RH: The diagnosis and typing of cardiac amyloidosis. Amyloid 2003, 10:127-129.
4. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:583-596.
5. Smith TJ, Kyle RA, Lie JT: Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 1984, 59:547-555.
6. Mueller PS, Edwards WD, Gertz MA: Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000, 109:181-188.
7. Dubrey SW, Cha K, Skinner M, et al.: Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997, 78:74-82.
8. Liao R, Jain M, Teller P, et al.: Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001, 104:1594-1597.
9. Brenner DA, Jain M, Pimentel DR, et al.: Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004, 94:1008-1010. This report demonstrates the direct effect of light chains on cardiac cellular function, supporting the concept that free light chains play a role in the progression of disease in patients with AL cardiac amyloidosis.
10. Dubrey S, Mendes L, Skinner M, Falk RH: Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med 1996, 125:481-484.
11. Kyle RA, Gertz MA: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995, 32:45-59.
12. Rahman JE, Helou EF, Gelzer-Bell R, et al.: Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004, 43:410-415.
13. Nordlinger M, Magnani B, Skinner M, Falk RH: Is elevated plasma b-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 2005, 96:982-984.
14. Dispenzieri A, Gertz MA, Kyle RA, et al.: Prognostication of survival using cardiac troponins and n-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004, 104:1881-1887.
15. Palladini G, Campana C, Klersy C, et al.: Serum n-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003, 107:2440-2445.
16. Pomfret EA, Lewis WD, Jenkins RL, et al.: Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 1998, 65:918-925.
17. Olofsson BO, Backman C, Karp K, Suhr OB: Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002, 73:745-751.
18. Yazaki M, Tokuda T, Nakamura A, et al.: Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000, 274:702-706.
19. Nardo B, Beltempo P, Bertelli R, et al.: Combined heart and liver transplantation in four adults with familial amyloidosis: Experience of a single center. Transplant Proc 2004, 36:645-647.
20. Klabunde T, Petrassi HM, Oza VB, et al.: Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 2000, 7:312-321.
21. Guidelines Working Group of UK Myeloma Forum, British Commitee for Standards in Haematology, British Society for Haematology: Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004, 125:681-700.
22. Skinner M, Sanchorawala V, Seldin DC, et al.: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85-93.
23. Dispenzieri A, Kyle RA, Gertz MA, et al.: Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003, 361:1787-1789.
24. Gertz MA, Comenzo R, Falk RH, et al.: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005, 79:319-328.
25. Palladini G, Perfetti V, Obici L, et al.: Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004, 103:2935-2938.
26. Sanchorawala V, Wright DG, Seldin DC, et al.: High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004, 33:381-388. This report demonstrates the efficacy of high-dose melphalan for treatment of patients with AL amyloidosis, including patients with cardiac involvement.
27. Trikas A, Rallidis L, Hawkins P, et al.: Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis. Am J Cardiol 1999, 84:1049-1054.
28. Hosenpud JD, Uretsky BF, Griffith BP, et al.: Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey. J Heart Transplant 1990, 9:346-350.
29. Thaunat O, Alyanakian MA, Varnous S, et al.: Long-term successful outcome of sequential cardiac and allogeneic bone marrow transplantations in severe AL amyloidosis. Bone Marrow Transplant 2005, 35:419-420. This report shows the feasibility of combining heart transplantation with subsequent high-dose chemotherapy supported by bone marrow transplantation for select patients with AL amyloidosis.
30. Alloni A, Pellegrini C, Ragni T, et al.: Heart transplantation in patients with amyloidosis: Single-center experience. Transplant Proc 2004, 36:643-644.
31. Kyle RA, Linos A, Beard CM, et al.: Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992, 79:1817-1822.
32. Murtagh B, Hammill SC, Gertz MA, et al.: Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005, 95:535-537.
33. Gertz MA, Falk RH, Skinner M, et al.: Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985, 55:1645.
34. Pollak A, Falk RH: Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993, 104:618-620.
35. Rubinow A, Skinner M, Cohen AS: Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981, 63:1285-1288.
36. Berk JL, Keane J, Seldin DC, et al.: Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003, 124:969-977.
37. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
38. Dubrey S, Pollak A, Skinner M, Falk RH: Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 1995, 74:541-544.
39. Palladini G, Malamani G, Co F, et al.: Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 2001, 24:1228-1233.
40. Hess EP, White RD: Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients. Resuscitation 2004, 60:105-111.
41. Wright BL, Grace AA, Goodman HJ: Implantation of a cardioverter- defibrillator in a patient with cardiac amyloidosis. Nat Clin Pract Cardiovasc Med 2006, 3:110-114.